| Original language | English |
|---|---|
| Pages (from-to) | 935-939 |
| Number of pages | 5 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 42 |
| Issue number | 8 |
| Publication status | Published - Aug 1 2015 |
Fingerprint
Protein-Tyrosine Kinases
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
II. Development and future prospects of the third-generation EGFR-tyrosine kinase inhibitor. / Sakata, Shinya; Iwama, Eiji; Okamoto, Isamu.
In: Japanese Journal of Cancer and Chemotherapy, Vol. 42, No. 8, 01.08.2015, p. 935-939.Research output: Contribution to journal › Article
Sakata, S, Iwama, E & Okamoto, I 2015, 'II. Development and future prospects of the third-generation EGFR-tyrosine kinase inhibitor', Japanese Journal of Cancer and Chemotherapy, vol. 42, no. 8, pp. 935-939.
Sakata S, Iwama E, Okamoto I. II. Development and future prospects of the third-generation EGFR-tyrosine kinase inhibitor. Japanese Journal of Cancer and Chemotherapy. 2015 Aug 1;42(8):935-939.
@article{5c738e0cb29b4d909e4c4ac06eb3f32d,
title = "II. Development and future prospects of the third-generation EGFR-tyrosine kinase inhibitor",
author = "Shinya Sakata and Eiji Iwama and Isamu Okamoto",
year = "2015",
month = "8",
day = "1",
language = "English",
volume = "42",
pages = "935--939",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",
}
TY - JOUR
T1 - II. Development and future prospects of the third-generation EGFR-tyrosine kinase inhibitor
AU - Sakata, Shinya
AU - Iwama, Eiji
AU - Okamoto, Isamu
PY - 2015/8/1
Y1 - 2015/8/1
UR - http://www.scopus.com/inward/record.url?scp=84978382729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978382729&partnerID=8YFLogxK
M3 - Article
C2 - 26353390
AN - SCOPUS:84978382729
VL - 42
SP - 935
EP - 939
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 8
ER -